Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NEW PRODUCTS
July 26, 2010
- Lorcaserin Induces Significant Weight Loss in PIII: Eisai
July 26, 2010
- Pariet to See Generics from 23 Companies in Nov.
July 26, 2010
- JELIS Trial Sub-Analysis Shows Significant Reduction in CAD by Epadel
July 26, 2010
- Foreign-Affiliated Research-Driven Companies Point out Need for Cautious Approach to Generics Business
July 26, 2010
- Dapagliflozin + Insulin Improve Glycemic Control in PIII: BMS, AZ
July 26, 2010
- Celgene's 2 Drugs for Multiple Myeloma Recommended for Approval
July 26, 2010
- Everolimus More Than Doubles PFS in pNET Patients
July 26, 2010
- All Candidates from Nichiiren Fail to Obtain Seat in Upper House
July 26, 2010
- Iressa Doubles PFS in Japanese NSCLC Patients with Mutated EGFR
July 26, 2010
- Parliamentary Secretary for Health Shinya Adachi Reelected
July 26, 2010
- Kobayashi to Develop More Class 1 OTC Drugs
July 26, 2010
- Dr Fujii Regains Seat in Upper House
July 26, 2010
- JPA to Renew Its Efforts to Increase Members' Awareness of New OTC Drug Sales System
July 26, 2010
- Standardize Interpretation of 1980 Notification: Chuikyo
July 26, 2010
- Erbitux Associated with Fewer Severe Infusion Reactions in Japan
July 26, 2010
- Seikagaku Submits Amended PMA for Gel-200 to the FDA
July 19, 2010
- Toa Eiyo: Sales of Long-Listed Drugs Continue to Drop
July 19, 2010
- Acquisition of New Platform Technologies Key for R&D: Dr Odaka of Takeda
July 19, 2010
- Number of DPC Hospitals Increases to 1,391
July 19, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…